Chronic Urticaria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?
The 7 major chronic urticaria markets reached a value of US$ 14.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 32.4 Million by 2034, exhibiting a growth rate (CAGR) of 7.97% during ?2024-2034?.
The chronic urticaria market has been comprehensively analyzed in IMARC's new report titled "Chronic Urticaria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?". Chronic urticaria is a common dermal disorder characterized by severely inflamed, well-encircled, swollen welts with sizes that range from a few millimeters to several centimeters or wider. The secretion of excessive quantities of histamine and other inflammatory mediators in the skin causes this disorder. The indications of chronic urticaria usually begin on the affected person's skin. These include clusters of welts that can appear on any body part. Further symptoms encompass welts that differ in size and form, as well as appear or disappear repetitively, itchiness that can be strenuous, a painful soreness all around the eyes, cheeks, and lips, flares caused by high temperatures, workouts, or strain, and clinical signs that last longer than six weeks and recur frequently, etc. The diagnosis of chronic urticaria is primarily clinical. The doctor may review the patient's medical history and ask questions regarding when and where the rash initially appeared, any genetic history of urticaria, and the patient's current skin condition. A physical examination that includes evaluating the pulse rate and characterizing and identifying present lesions and their severity with the help of a skin biopsy is required for further diagnosis. To rule out any underlying issues, the doctor may also examine the eyes, ears, nose, throat, lymphoid tissue, stomach, and locomotor system.
The rising prevalence of allergic disorders and infections owing to several associated triggering factors, such as diet, alcohol, heat and friction, mental stress, etc., is primarily driving the global chronic urticaria market. In addition to this, the growing incidences of autoimmune ailments, such as celiac disease, rheumatoid arthritis, Type 1 diabetes, etc., which increase the risk of chronic urticaria are also positively influencing the market growth. Moreover, the introduction of advanced validated instruments that can quantify the severity of the ailment is further propelling the market growth. Besides this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness regarding the significant psychosocial effects of chronic urticaria, especially stigmatization. This, in turn, is also acting as another growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to evaluate the safety and efficacy, mechanism of action, and dosing of biologics, which is further bolstering the global market. Numerous other factors, including the emerging popularity of second-generation antihistamines, such as fexofenadine HCl, and the development of preventive and pharmacological approaches to control the disabling symptoms suffered by patients, are expected to drive the global chronic urticaria market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic urticaria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic urticaria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic urticaria market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: ?2018-2023?
Market Forecast: ?2024-2034?
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic urticaria market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic urticaria market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic urticaria marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic urticaria market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic urticaria market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic urticaria market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the chronic urticaria patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic urticaria ?
What will be the growth rate of patients across the seven major markets?
Chronic Urticaria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic urticaria drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic urticaria market?
The chronic urticaria market has been comprehensively analyzed in IMARC's new report titled "Chronic Urticaria Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ?2024-2034?". Chronic urticaria is a common dermal disorder characterized by severely inflamed, well-encircled, swollen welts with sizes that range from a few millimeters to several centimeters or wider. The secretion of excessive quantities of histamine and other inflammatory mediators in the skin causes this disorder. The indications of chronic urticaria usually begin on the affected person's skin. These include clusters of welts that can appear on any body part. Further symptoms encompass welts that differ in size and form, as well as appear or disappear repetitively, itchiness that can be strenuous, a painful soreness all around the eyes, cheeks, and lips, flares caused by high temperatures, workouts, or strain, and clinical signs that last longer than six weeks and recur frequently, etc. The diagnosis of chronic urticaria is primarily clinical. The doctor may review the patient's medical history and ask questions regarding when and where the rash initially appeared, any genetic history of urticaria, and the patient's current skin condition. A physical examination that includes evaluating the pulse rate and characterizing and identifying present lesions and their severity with the help of a skin biopsy is required for further diagnosis. To rule out any underlying issues, the doctor may also examine the eyes, ears, nose, throat, lymphoid tissue, stomach, and locomotor system.
The rising prevalence of allergic disorders and infections owing to several associated triggering factors, such as diet, alcohol, heat and friction, mental stress, etc., is primarily driving the global chronic urticaria market. In addition to this, the growing incidences of autoimmune ailments, such as celiac disease, rheumatoid arthritis, Type 1 diabetes, etc., which increase the risk of chronic urticaria are also positively influencing the market growth. Moreover, the introduction of advanced validated instruments that can quantify the severity of the ailment is further propelling the market growth. Besides this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness regarding the significant psychosocial effects of chronic urticaria, especially stigmatization. This, in turn, is also acting as another growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to evaluate the safety and efficacy, mechanism of action, and dosing of biologics, which is further bolstering the global market. Numerous other factors, including the emerging popularity of second-generation antihistamines, such as fexofenadine HCl, and the development of preventive and pharmacological approaches to control the disabling symptoms suffered by patients, are expected to drive the global chronic urticaria market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic urticaria market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic urticaria and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic urticaria market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: ?2018-2023?
Market Forecast: ?2024-2034?
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic urticaria market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic urticaria market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic urticaria marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic urticaria market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic urticaria market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic urticaria market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the chronic urticaria patient pool (?2018-2023?) across the seven major markets?
What would be the forecasted patient pool (?2024-2034?) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic urticaria ?
What will be the growth rate of patients across the seven major markets?
Chronic Urticaria: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic urticaria drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic urticaria market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC URTICARIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 CHRONIC URTICARIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC URTICARIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 CHRONIC URTICARIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC URTICARIA - UNMET NEEDS
10 CHRONIC URTICARIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC URTICARIA - MARKETED PRODUCTS
11.1 List of Chronic Urticaria Marketed Drugs Across the Top 7 Markets
11.1.1 Fexofenadine - Sanofi-Aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Omalizumab
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Desloratadine - Merck & Co.
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Levocetirizine - Sanofi-Aventis/UCB
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC URTICARIA - PIPELINE DRUGS
12.1 List of Chronic Urticaria Pipeline Drugs Across the Top 7 Markets
12.1.1 Dupilumab - Regeneron/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Rilzabrutinib - Principia Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Remibrutinib - Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Legelizumab - Novartis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC URTICARIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHRONIC URTICARIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Chronic Urticaria - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Chronic Urticaria - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Chronic Urticaria - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Chronic Urticaria - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Chronic Urticaria - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Chronic Urticaria - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Chronic Urticaria - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Chronic Urticaria - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Chronic Urticaria - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Chronic Urticaria - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Chronic Urticaria - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Chronic Urticaria - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Chronic Urticaria - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Chronic Urticaria - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Chronic Urticaria - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Chronic Urticaria - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Chronic Urticaria - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Chronic Urticaria - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Chronic Urticaria - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Chronic Urticaria - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Chronic Urticaria - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Chronic Urticaria - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Chronic Urticaria - Access and Reimbursement Overview
15 CHRONIC URTICARIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 CHRONIC URTICARIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC URTICARIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (?2018-2023?) and Forecast (?2024-2034?)
4.3 Market Overview (?2018-2023?) and Forecast (?2024-2034?)
4.4 Competitive Intelligence
5 CHRONIC URTICARIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC URTICARIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (?2018-2023?)
7.2.2 Epidemiology Forecast (?2024-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (?2018-2023?)
7.3.2 Epidemiology Forecast (?2024-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (?2018-2023?)
7.4.2 Epidemiology Forecast (?2024-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (?2018-2023?)
7.5.2 Epidemiology Forecast (?2024-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (?2018-2023?)
7.6.2 Epidemiology Forecast (?2024-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (?2018-2023?)
7.7.2 Epidemiology Forecast (?2024-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (?2018-2023?)
7.8.2 Epidemiology Forecast (?2024-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (?2018-2023?)
7.9.2 Epidemiology Forecast (?2024-2034?)
8 CHRONIC URTICARIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC URTICARIA - UNMET NEEDS
10 CHRONIC URTICARIA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC URTICARIA - MARKETED PRODUCTS
11.1 List of Chronic Urticaria Marketed Drugs Across the Top 7 Markets
11.1.1 Fexofenadine - Sanofi-Aventis
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Omalizumab
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Desloratadine - Merck & Co.
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Levocetirizine - Sanofi-Aventis/UCB
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC URTICARIA - PIPELINE DRUGS
12.1 List of Chronic Urticaria Pipeline Drugs Across the Top 7 Markets
12.1.1 Dupilumab - Regeneron/Sanofi
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Rilzabrutinib - Principia Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Remibrutinib - Novartis
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Benralizumab - AstraZeneca/Kyowa Kirin
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Legelizumab - Novartis
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC URTICARIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 CHRONIC URTICARIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Chronic Urticaria - Market Size
14.2.1.1 Market Size (?2018-2023?)
14.2.1.2 Market Forecast (?2024-2034?)
14.2.2 Chronic Urticaria - Market Size by Therapies
14.2.2.1 Market Size by Therapies (?2018-2023?)
14.2.2.2 Market Forecast by Therapies (?2024-2034?)
14.3 Market Scenario - United States
14.3.1 Chronic Urticaria - Market Size
14.3.1.1 Market Size (?2018-2023?)
14.3.1.2 Market Forecast (?2024-2034?)
14.3.2 Chronic Urticaria - Market Size by Therapies
14.3.2.1 Market Size by Therapies (?2018-2023?)
14.3.2.2 Market Forecast by Therapies (?2024-2034?)
14.3.3 Chronic Urticaria - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Chronic Urticaria - Market Size
14.4.1.1 Market Size (?2018-2023?)
14.4.1.2 Market Forecast (?2024-2034?)
14.4.2 Chronic Urticaria - Market Size by Therapies
14.4.2.1 Market Size by Therapies (?2018-2023?)
14.4.2.2 Market Forecast by Therapies (?2024-2034?)
14.4.3 Chronic Urticaria - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Chronic Urticaria - Market Size
14.5.1.1 Market Size (?2018-2023?)
14.5.1.2 Market Forecast (?2024-2034?)
14.5.2 Chronic Urticaria - Market Size by Therapies
14.5.2.1 Market Size by Therapies (?2018-2023?)
14.5.2.2 Market Forecast by Therapies (?2024-2034?)
14.5.3 Chronic Urticaria - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Chronic Urticaria - Market Size
14.6.1.1 Market Size (?2018-2023?)
14.6.1.2 Market Forecast (?2024-2034?)
14.6.2 Chronic Urticaria - Market Size by Therapies
14.6.2.1 Market Size by Therapies (?2018-2023?)
14.6.2.2 Market Forecast by Therapies (?2024-2034?)
14.6.3 Chronic Urticaria - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Chronic Urticaria - Market Size
14.7.1.1 Market Size (?2018-2023?)
14.7.1.2 Market Forecast (?2024-2034?)
14.7.2 Chronic Urticaria - Market Size by Therapies
14.7.2.1 Market Size by Therapies (?2018-2023?)
14.7.2.2 Market Forecast by Therapies (?2024-2034?)
14.7.3 Chronic Urticaria - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Chronic Urticaria - Market Size
14.8.1.1 Market Size (?2018-2023?)
14.8.1.2 Market Forecast (?2024-2034?)
14.8.2 Chronic Urticaria - Market Size by Therapies
14.8.2.1 Market Size by Therapies (?2018-2023?)
14.8.2.2 Market Forecast by Therapies (?2024-2034?)
14.8.3 Chronic Urticaria - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Chronic Urticaria - Market Size
14.9.1.1 Market Size (?2018-2023?)
14.9.1.2 Market Forecast (?2024-2034?)
14.9.2 Chronic Urticaria - Market Size by Therapies
14.9.2.1 Market Size by Therapies (?2018-2023?)
14.9.2.2 Market Forecast by Therapies (?2024-2034?)
14.9.3 Chronic Urticaria - Access and Reimbursement Overview
15 CHRONIC URTICARIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 CHRONIC URTICARIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
